Search bioRxiv⌕ Search

Biology subjects

Wolberg, A. S.

Publications and source records attributed to Wolberg, A. S..

2 recordsLinked to original sources

Hypoalbuminemia Increases Fibrin Clot Density and Impairs Fibrinolysis

BackgroundHypoalbuminemia is a thrombotic disease risk biomarker. Albumin is a negative acute phase reactant and may thus be an indirect biomarker of thromboinflammation. However, nephrotic syndrome (resulting from non-inflammatory proteinuric glomerular disease) causes both hypoalbuminemia and elevated thrombotic risk. Hypofibrinolysis has been observed in nephrotic syndrome and published data suggest that albumin may directly enhance fibrinolysis. These observations suggest that albumin may directly influence thrombotic risk. ObjectiveTo test the hypothesis that hypoalbuminemia impairs fibrinolysis. MethodsHypoalbuminemic blood and plasma from nephrotic syndrome rat models and nephrotic patients were analyzed by thromboelastometry, clot lysis assays, fibrin clot turbidity, confocal microscopy, and immunoblotting. Some studies were conducted without vs. with albumin repletion. Plasma from an analbuminemic mutant rat model was used to confirm albumin-dependent observations. ResultsHypoalbuminemia was associated with hypofibrinolysis in nephrotic whole blood. Albumin levels were positively associated with fibrinolysis in both nephrotic rat and patient plasma. Hypoalbuminemia accelerated fibrin clot formation in nephrotic rat plasma. Dense fibrin clots are known to be resistant to fibrinolysis and fibrin clot network density was increased in hypoalbuminemic plasma clots from both nephrotic rats and patients. Clots formed from hypoalbuminemic plasma contained less albumin than controls, and repletion with recombinant albumin to healthy control levels corrected both fibrin network density and fibrinolysis in nephrotic and analbuminemic rat plasma. ConclusionThese data show that albumin directly increases fibrin network porosity and enhances fibrinolysis. Hypoalbuminemia may mechanistically contribute to nephrotic syndrome thrombotic complications and may similarly increase thrombotic risk in other hypoalbuminemic conditions.

physiology↗

The plasma Factor XIII heterotetrameric complex structure: unexpected unequal pairing within a symmetric complex

Factor XIII (FXIII) is a predominant determinant of clot stability, strength, and composition. Plasma FXIII circulates as a pro-transglutaminase with 2 catalytic A subunits and 2 carrier-protective B subunits in a heterotetramer (FXIII-A2B2). FXIII-A2 and -B2 subunits are synthesized separately and then assembled in plasma. Following proteolytic activation by thrombin and calcium-mediated dissociation of the B-subunits, activated FXIII (FXIIIa) covalently cross-links fibrin, promoting clot stability. The zymogen and active states of the FXIII-A subunits have been structurally characterized; however, the structure of FXIII-B subunits and the FXIII-A2B2 complex have remained elusive. Using integrative hybrid approaches including atomic force microscopy, cross-linking mass spectrometry, and computational approaches, we have constructed the first all-atom model of the FXIII-A2B2 complex. We also used molecular dynamic simulations in combination with isothermal titration calorimetry to characterize FXIII-A2B2 assembly, activation, and dissociation. Our data reveal unequal pairing of individual subunit monomers in an otherwise symmetric complex, and suggest this unusual structure is critical for both assembly and activation of this complex. Our findings enhance understanding of mechanisms associating FXIII-A2B2 mutations with disease and have important implications for the rational design of molecules to alter FXIII assembly and/or activity to reduce bleeding and thrombotic complications.

molecular biology↗